Modern Therapies Offer a Way to Reach the Brain in HER2+ Metastatic Breast Cancer

August 14, 2020

In an interview with Targeted Oncology, Stephanie Weiss, MD, reviewed the treatment landscape for HER2-positive metastatic breast cancer and gave her predictions on how the paradigm will evolve for patients with brain metastases now that tucatinib has demonstrated efficacy.

Pooled Analysis Reveals Long-Term Effect on QoL and Cognitive Outcomes From Radiation for Brain Metastases

August 14, 2020

In the first pooled prospective study to show the long-term outcomes of cranial radiation in patients with limited brain metastases, it was observed that whole-brain radiotherapy was associated with worse cognitive outcomes and mixed quality of life compared with stereotactic radiosurgery for these patients over time, according to a presentation from Joshua Palmer, MD, at the 2020 Virtual Conference on Brain Metastases.

Cerebrospinal Fluid CTCs May Help Predict Outcomes in Leptomeningeal Disease

August 14, 2020

Quantification of circulating tumor cells in cerebrospinal fluid can be used to predict survival outcomes in patients with newly diagnosed leptomeningeal disease, according to the results of a retrospective analysis presented during the Society of Neuro-Oncology’s 2020 Virtual Conference on Brain Metastases .

Radiosurgery Improves Clinical Outcomes in Brain Metastasis Treatment

August 14, 2020

Joshua Palmer, MD, discusses a pooled analysis of 2 randomized clinical trials that compared how clinical outcomes and quality of life were impacted with stereotactic radiosurgery versus whole-brain radiation therapy in patients with brain metastases.

Tucatinib Combination Demonstrates Multiple Positive Responses in HER2-Positive Metastatic Breast Cancer

August 14, 2020

Multiple positive responses were observed in an exploratory efficacy analysis evaluating tucatinib in combination with trastuzumab and capecitabine in patients with previously treated HER2-positive metastatic breast cancer with brain metastases in the previously reported HER2CLIMB trial.

Pazopanib Activity in RAI-Refractory Differentiated Thyroid Cancer Corroborated in Prospective Study

August 14, 2020

Pazopanib was confirmed active with manageable toxicities as treatment of patients with progressive radioactive-iodine–refractory differentiated thyroid cancer, based on results of a prospective study.

Roberge Explains the Role of Radiotherapy in Treatment of Brain Metastasis

August 14, 2020

David Roberge, MD, discusses the current role of radiosurgery in the brain metastasis treatment paradigm, a topic he reviewed during a presentation at the 2020 Society of Neuro-Oncology Conference on Brain Metastases.

HER2CLIMB Regimen Delays CNS Progression in HER2+ Metastatic Breast Cancer

August 14, 2020

In an interview with Targeted Oncology following the SNO Brain Metastasis Meeting, Nancy Lin, MD, discussed the treatment of brain metastases in HER2-positive metastatic breast cancer in general, as well as the subgroup analysis of patients with brain metastases in the phase 2 HER2CLIMB clinical trial.

Investigating Prognostic Markers for OS With LuPSMA Treatment in mCRPC

August 14, 2020

Andrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.

Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer

August 14, 2020

Research into mutations in the gene encoding the epidermal growth factor receptor protein has revolutionized non–small cell lung cancer treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.

ODAC Votes Yes to FDA Approval of Remestemcel-L in Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease

August 14, 2020

The Oncologic Drugs Advisory Committee of the FDA voted 8 to 2 in favor of the approval of remestemcel-L, an allogeneic cell therapy, for the treatment of children with steroid-refractory acute graft-versus-host disease.

Novel IAP Inhibitor Shows Significant OS Benefit for High-Risk Head and Neck Cancer

August 13, 2020

Debio 1143, a potential first-in-class inhibitor of apoptosis proteins, demonstrated a statistically and clinically significant overall survival improvement when used in combination with chemoradiotherapy as treatment of patients with high-risk locally advanced squamous cell carcinoma of the head and neck, according to a press release from Debiopharm.